Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
15 May 2024
|
|
20:44 | Medication reconciliation 2 changes history +536 [Badgettrg (2×)] | |||
|
|
20:44 (cur | prev) +1 Badgettrg talk contribs (→Frequency of reconciliation errors) | ||||
|
|
20:43 (cur | prev) +535 Badgettrg talk contribs | ||||
| 14:58 | Vamorolone diffhist +11,928 Rafael Garcia talk contribs | ||||
|
|
14:21 | User:Archana.vajjala 2 changes history −24 [Archana.vajjala (2×)] | |||
|
|
14:21 (cur | prev) −22 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
12:16 (cur | prev) −2 Archana.vajjala talk contribs Tag: Visual edit | ||||
|
|
N 10:59 | Lodoxamide 2 changes history +6,537 [Alara E. Dagsali (2×)] | |||
|
|
10:59 (cur | prev) +3 Alara E. Dagsali talk contribs | ||||
| N |
|
10:58 (cur | prev) +6,534 Alara E. Dagsali talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |genericName=Alomide |indicationType=treatment |indication=ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1% is indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. |adverseReactions=During clinical studies of ALOMIDE® (lodoxamide tromethamine ophthalmic solution) 0.1%, the most frequently reported ocular adve...") | |||
|
|
04:40 | Trofinetide 2 changes history +176 [Alen Antony (2×)] | |||
|
|
04:40 (cur | prev) +41 Alen Antony talk contribs | ||||
|
|
04:40 (cur | prev) +135 Alen Antony talk contribs | ||||
|
|
04:28 | Fezolinetant 8 changes history +4,781 [Alen Antony (8×)] | |||
|
|
04:28 (cur | prev) +1,695 Alen Antony talk contribs | ||||
|
|
04:21 (cur | prev) +1,499 Alen Antony talk contribs | ||||
|
|
03:44 (cur | prev) +174 Alen Antony talk contribs | ||||
|
|
03:37 (cur | prev) +19 Alen Antony talk contribs | ||||
|
|
02:46 (cur | prev) +589 Alen Antony talk contribs | ||||
|
|
02:24 (cur | prev) +234 Alen Antony talk contribs | ||||
|
|
01:32 (cur | prev) +512 Alen Antony talk contribs | ||||
|
|
01:09 (cur | prev) +59 Alen Antony talk contribs | ||||
|
|
m 03:31 | Non-degenerate nucleotides per response element 2 changes history −129 [Marshallsumter (2×)] | |||
| m |
|
03:31 (cur | prev) −3 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
03:27 (cur | prev) −126 Marshallsumter talk contribs (→Tabulation of counts) | |||
14 May 2024
|
|
21:44 | Fezolinetant 2 changes history +817 [Alen Antony (2×)] | |||
|
|
21:44 (cur | prev) +723 Alen Antony talk contribs | ||||
|
|
21:34 (cur | prev) +94 Alen Antony talk contribs | ||||
|
|
m 20:44 | Non-degenerate nucleotides per response element 4 changes history +356 [Marshallsumter (4×)] | |||
| m |
|
20:44 (cur | prev) +391 Marshallsumter talk contribs (→Averages per Orders) | |||
| m |
|
20:07 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:40 (cur | prev) 0 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:23 (cur | prev) −35 Marshallsumter talk contribs | |||
| 04:55 | Somatrogon-ghla diffhist +52 Kosar Doraghi talk contribs | ||||
13 May 2024
| N 23:48 | Fezolinetant diffhist +84 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |OTC=Yes |genericName=fezolinetant }}") | ||||
|
|
N 23:46 | Nirsevimab-alip 2 changes history +5,780 [Alen Antony (2×)] | |||
|
|
23:46 (cur | prev) +3,844 Alen Antony talk contribs | ||||
| N |
|
14:50 (cur | prev) +1,936 Alen Antony talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=Nirsevimab-alip |aOrAn=a |drugClass=human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody |indicationType=prevention |indication=Respiratory Syncytial Virus (RSV) lower respiratory tract disease for neonates and infants born during or entering their first RSV season and children up to 24 years of age who are vulnerable to severe RSV disease in their second RSV season. |adverseReactions=rashes and injection...") | |||
|
|
m 22:04 | Non-degenerate nucleotides per response element 3 changes history −233 [Marshallsumter (3×)] | |||
| m |
|
22:04 (cur | prev) −60 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
08:12 (cur | prev) −2 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
07:26 (cur | prev) −171 Marshallsumter talk contribs (→Tabulation of counts) | |||
| N 20:38 | Talquetamab-tgvs diffhist +2,766 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Talquetamab-tgvs |aOrAn=a |drugClass=bispecific GPRC5D-directed CD3 T-cell engager |indicationType=treatment |indication=TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent...") | ||||
| 14:23 | Non-alcoholic fatty liver disease epidemiology and demographics diffhist +1,197 Badgettrg talk contribs (→Overview) | ||||
12 May 2024
|
|
m 23:34 | Non-degenerate nucleotides per response element 3 changes history −150 [Marshallsumter (3×)] | |||
| m |
|
23:34 (cur | prev) −149 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
22:44 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
| m |
|
22:34 (cur | prev) +48 Marshallsumter talk contribs (→Tabulation of counts) | |||
|
|
23:08 | Vitamin D 2 changes history +1,636 [Badgettrg (2×)] | |||
|
|
23:08 (cur | prev) +503 Badgettrg talk contribs (→Medical uses) | ||||
|
|
23:00 (cur | prev) +1,133 Badgettrg talk contribs (→Role in depression prevention) | ||||